Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: Kite Pharma
Yahoo Beta:1.08

Company Description:  Kite Pharma develops new immunotheraputic drugs for cancer.

Purchase Date:18 Nov 2016 Sale Date:30 Aug 2017
Purchase Price:$51.75 Sale Price:$178.03
  --Split Adjusted:$51.75  --Split Adjusted:$178.03
Shares Purchased:35 Shares Sold:35
  --Split Adjusted:35  --Split Adjusted:35
Transaction Fee:$9.99 Transaction Fee:$7.10
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$62.51 High$0.00
Date15 Aug 2016 Date01 Jan 1996
Low$40.01 Low$0.00
Date03 Nov 2016 Date01 Jan 1996
S&P (Purchase Date):$2,183.49 S&P (Sale Date):$2,448.47

Timing:  The stock is trading near the middle of its six month range. The price has risen significantly in recent weeks.
Reason:  Kite Pharma has several drugs in clinical trials that use immunotherapy to attack cancer cells. If successful, these drugs have the potential to effect cures with minimal side effects. Kite Pharma is the first mover in what is a very exciting area. Its first product was successful in clinical trials and is expected to come to market in 2017. The company has a large pipeline of drugs in development.

Timing:  0
Reason:  Gilead has made an offer to buy KITE in an all cash offer of $180 per share. The current price reflects almost the full purchase price and there have been some legal challenges. There is very limited upside and some risk, so we decided to sell.

S&P Gain: 12.14 % Annualized Gain: 17.9%
Stock Gain: 244.02 % Annualized Gain: 490.3%

Net Holding Return ($): $4,402.71
Net Holding Return (%): 241.74 %